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ONCE-DAILY VERSUS DIVIDED DOSAGE LITHIUM 
THERAPY IN ACUTE MANIA 
KP.SURESH, K.M.R.PRASAD, RAJESH MOHAN, CHITTARANJAN ANDRADE, 
M.V.ASHOK, S.K.CHATURVEDI, K.N.SREENIVAS 
The aim oft/ic study was to compare once-daily with divided dosage lithium treatment in acute mania. 
In 79 retrospectively studied subjects who met the DSMIII-R criteria for mania, 26 independent and 
dependent variables were analyzed. The two groups of patients (categorized according to dosage 
schedule) were broadly compat able with respect to demographic and clinical characteristics. The (H« 
groups also did not differ on the outcome measures of lithium efficacy ami lithium adverse effects. It 
is concluded tliat single dose lithium tlwrapy is clinically comparable with divided dose lithium therapy 
in acute mania. Possible advantages of switching over to once-daily lithium regimes are discussed. 
Key words: lithium, acute mania. 
INTRODUCTION 
Lithium is the cornerstone in the treatment of a 
manic episode and in the prophylaxis against mood 
swings in bipolar affective disorder. Its efficacy in 
this respect is well established. In India, lithium is 
usually given daily in two or three divided doses 
while in many European countries a single daily 
dose is the preferred regimen (Grof et al, 1980; 
Schouetai, 1982;Kehoe&Mander, 1992; Bramble, 
1992). Whereas currently trials are being conducted 
on the usefulness of lithium administration on alter-
nate days (Jensen et al, 1990), it is paradoxical that 
most of the psychiatrists in our country are not even 
using single dose lithium therapy. 
In this study, we therefore compared acutely 
manic subjects receiving single dose lithium with 
those receiving divided dosage in order to assess 
differences, if any, in terms of efficacy and adverse 
effects. The main hypothesis addressed was that 
once daily lithium would be associated with 
equivalent therapeutic outcome and equivalent or 
fewer side effects compared to divided dose lithium. 
MATERIALS AND METHODS 
This study was a retrospective chart review of 
patients from a single clinical unit in an urban, 
teaching, postgraduate psychiatric institute. Sub-
jects who had registered between January 1991 and 
December 1992, who met the DSM-IIIR (American 
Psychiatric Association, 1987) criteria for acute 
mania, and who were on therapeutic lithium, were 
included. Since a rater would have to systematically 
sift through reams of case notes, it would be impos-
sible for him to remain blind to the lithium dosage 
schedule. Hence, the charts were evaluated by not 
one but three raters (KPS, RM & KMRP). 
All decisions were based on mutual agreement, 
and data were recorded on a semi-structured profor-
ma. It was hoped this process would reduce potential 
bias, if any, in ratings. 
Seventy nine subjects met the study criteria; of 
these, 39 had received single dose lithium and 40 had 
received divided dose lithium. I'iftcen independent 
variables (demographic and clinical such as age, sex, 
previous episodes, family history, previous lithium 
response, symptom profile etc), and eleven depend-
ent variables (lithium dose, serum level, need for 
additional treatment, adverse drug reactions etc) 
were studied. 
Different variables were operational ized as fol-
lows: Lithium dose was defined as the maximum 
dose (during acute therapy) that was sustained in 
order to obtain treatment response. The serum 
lithium level at this dose was recorded. The mean 
duration of the episode after starting lithium was the 
time from starting lithium to the onset of euthymia. 
Additional treatment was defined as minimal 
(only SOS injections, during the acute phase). 
moderate (addition of neuroleptics for a short dura-
tion, lithium being the principal drug) and much 
(neuroleptics / LCT being the principal therapy, with 
lithium being the adjunct). Adverse drug reactions 
like gastritis, tremors, polyuria, hypothyroidism etc., 
were rated only if they were clearly recorded in the 
case file as being due to lithium. ITie duration of 
hospitalization was directly read off from the charts; 
fitness fordischarge in these patients had been based 
on the clinical judgement of three consultant 
psychiatrists. 
The two groups were compared with respect to 
the above variables using the Chi square and Rshcr's 
exact probability two tailed tests for categorical data. 
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and the independent sample t test for quantitative 
data. The Mann-Whitney U test was used when the 
assumptions for parametric statistical testing were ' 
not met. 
RESULTS 
Sample description: 
Subjects who were on single dose lithium (n= 39) 
had a mean age of thirty one years and the 
male:fcmale ratio was 7:1. The mean age of divided 
dose lithium subjects (n = 40) was twenty nine years 
and the male:female ratio was 1.6:1. Though the 
mean age in the two groups was comparable, there 
was a significantly greater proportion of females in 
the divided dose group. 
The two groups were comparable in the total 
number of affective episodes, but the single dose 
group had experienced significantly more depres-
sive episodes (Table 1). The groups were com-
parable with respect to family history of affective 
disorder and of non-affective psychosis and with 
respect to past history of lithium response. The two 
Table 1 
Demographic and clinical characteristics 
Variables Single dose Divided dose Significance 
(n=39) (n=40) 
1. Age (years) 31.1 ±11.1 28.9 * 10.6 t=0.88;df 77 
Mean*SD p>0.10 
2. Sex: male 34 24 X*=5.45;df1 
female 5 16 p<0.02 
3. Past history 22(56.4) 21(52.5) X
2=0.2;df1 
of mania p>0.1 
4Past history 12(30.7) 4(10.0) X
2=4.07;df1 
of depression p<0.05 
5. Family history 3(7.7) 7(17.5) FEP>0.1 
of affective 
disorder 
6. Family history 8(20.5) 5(12.5) X
2=0.4.43; df 1 
of noneffective p>0.1 
psychosis 
7.Mean (* SD) 
duration of 56.8* 88.1762.9*63.6 Mann-Whitney U 
episode before test, Z=1.76 
starting lithium p >0.05 
(in days) 
8 Past history of 
lithium response 0(0) 2(5.0) FEP>0.1 
For variables 2,3,4,5,6 and 8 figures refer to number of 
cases 
groups did not differ significantly with respect to the 
clinical features of the index episode of mania. 
The two groups did not differ significantly in any 
of the 3 categories of dependent variable exam ined. 
These categories were lithium dose and level char-
acteristics, efficacy measures and adverse effect 
measures (Table 2). 
Table 2 
Dependent variables 
Variables Single dose Divided dose Significance 
(n=39) (n=40) 
1.Lithium 1046.2* 166.8 1095.5* 209.9t=1.14;df 77 
(mg/day) p >0.2 
2. Serum lithium 0.7* 0.2 0.8 * 0.2 t= 1.09; df 49 
level (meq/L) p >0.2 
3. Mean (SD) 
duration of 
episode after 29.3* 23.1 25.8 * 21.8 2=0.4, p> 0.5 
starting lithium 
(in days) 
4. Mean duration of 
hospitalization 28.0*14.9 34.0*20.9 2=1.02, p>0.2 
(in days) 
5 Need for 
additional 30(76.9) 35(87.5) X
2=0.88;d<1 
treatment p >0.2 
6. Nature of additional treatment 
Nil 9(23.1) 5(12.5) 
Minimal 9(23.1) 5(12.5) FEP>0.05 
Moderate 19(487) 24(60.0) p>0.1 
Much 2(5.1) 6(15.0) 
7. Adverse 3 (7.7) 
reactions 
8. Need to 0(0.0) 
decrease 
lithium dose 
9. Need to stop 1 (2.6) 
lithium 
10. Need to change 
lithium dosage 0 (0.0) 
schedule 
7(17.5) 
3 (7.5) 
2 (5.0) 
3(7.5) 
X
2=1.03;df 1 
p>0.2 
FEP >0.05 
p> 0.1 
FEP> 0.05 
p>0.1 
FEP>005 
p >0 1 
For variables 5 to10 figures refer to number of cases; 
figures within brackets denote percentages. LITHIUM THERAPY IN MANIA 
Since sex distribution differed significantly be-
tween the two groups, the effect of sex on the de-
pendent variables was analyzed to ascertain whether 
it could have caused a bias. It was found that all 
dependent measures were independent of sex. 
Likewise, the greater number of depressive episodes 
in single dose group was found not to influence the 
results. 
DISCUSSION 
The results of the study indicate that single dose 
lithium is comparable to divided dose lithium 
therapy in acute mania. These results are in keeping 
with the results of many other studies (Perry et al, 
1981; Muir et al, 1989). Most studies have looked at 
the renal side effects of long term lithium therapy in 
single daily and divided dose regimens. Perry et al 
(1981) found no significant difference between the 
two groups with respect to serum half-lives or renal 
lithium clearance levels and concluded that the 
average steady state serum lithium concentration is 
unchanged by conversion to single daily doses. 
Moreover, if given once daily, a higher 12 hour 
serum lithium concentration can be achieved, and it 
is this concentration that is believed to correlate with 
the therapeutic efficacy of lithium (Amdisen, 1975). 
In this study, single dose subjects needed less dose 
per day compared to divided dose subjects, though 
the finding did not reach statistical significance. 
Studies have shown that the mean exposure to 
lithium in the two regimens is about the same, if 
measured as the area under the two different curves 
of serum lithium per 24 hours. This is due to a diumal 
variation in renal clearance, which is lower at night 
(Lauritsen et al, 1981), when the lithium concentra-
tion would be high if the drug were administered in 
a single evening dose. 
Another advantage of single dose lithium at night 
is that for at least 12 hours during the day, the scrum 
level falls below the 12 hour concentration, which is 
believed to decrease the polyuria associated with 
lithium therapy (Plenge & Mellerup, 1986). 
The majority of adverse drug reactions in our 
subjects were lithium induced tremors. These oc-
curred less in single dose subjects, thought not to a 
statistically significant extent. Incidentally, observa-
tions of fewer adverse reactions and better accep-
tance of single dose lithium are similar to those for 
most other psychotropics, e.g, tricyclic antidepres-
sants. The single most important advantage of single 
dose lithium is better drug compliance. Taking 
lithium two or three times a day is obviously less 
convenient, especially for working individuals, than 
taking a single night dose. The psychological effects 
ofbeing rem inded of the presence of a mental illness 
twice or thrice a day may also be more damaging. 
In conclusion, single dose lithium therapy was 
found to be comparable to divided dose therapy in 
acute mania. Hence, single dose lithium should be 
preferred in the management of acute mania, in order 
to improve compliance and in view of the other 
potential benefits discussed above. 
REFERENCES 
Amdisen, A. (1975) Sustained release preparations 
of lithium. InLithium Research andtherapy, (Ed 
F.N.Johnson). Orlando: Academic 
American Psychiatric Association (1987) Diag-
nostic and Statistical Manual of Mental Disor-
ders, 3rd edition revised. Washington DC: 
American Psychiatric Association. 
Bramble, D. (1992) A survey of lithium use in the 
elderly. International Journal of Geriatric 
Psychiatry, 7,819-826. 
Grof, P., MacCrimmon, DJ. & Smith, E.K.M. 
(1980) Long-term lithium treatment and the kid-
ney. Canadian Journal of Psychiatry, 25, 535-
543. 
Jensen, II. V., Olufsson, K., Bille, A., Andersen, J., 
Mellerup, E.T. & Plenge, P. (1990) Lithium 
every second day. A new treatment regimen? 
Lithium, 1,55-58. 
Kehoe, R.F. & Mander, A.J. (1992) Lithium treat-
ment prescribing and monitoring habits in hospi-
tal and general practice. British Medical Journal, 
304, 552-554. 
Lauritsen, BJ., Mellerup, E.T., Plenge, P., Ras-
mussen, S., Vestergaard, P. & Schou, M. 
(1981) Serum lithium concentration around the 
clock with different treatment regimens and diur-
nal variation of renal lithium clearance. Acta 
Psychiatrica Scandinavica, 64. 314-319. 
Muir, A., Davidson, R., Silverstone, T., Duwnay, 
A. & Forsling, M.L.(1989) Two regimens of 
lithium prophylaxis and renal function. Acta 
Psychiatrica Scandinavica, 80, 579-583. 
Perry, PJ., Uunner, FJ., Iluhn, R.L., Tsuang, 
M.T. & Berg, MJ. (1981) Lithium kinetics in 
single daily dosing. Ada Psychiatrica Scan-
dinavica, 64,281-294. 
11 K.P.SURESHETAL 
Pledge, P. & Mellerup, E.T. (1986) Lithium and regimen and renal water handling. The sig-
the kidney. Is one daily dose better than two? nificance of dosage pattern and tablet type ex-
Comprehensive Psychiatry, 27, 336-342. amined through comparison of results from two 
Schou, M., Amdisen, A., Thomsen, K., Vester- clinics with different treatment regimens. 
guard, P., Helmar, O., Mellerup, E.T., Plenge, Psychopharmacology, 77, 387-390. 
P. & Rufoelsen, OJ. (1982) Lithium treatment 
K.P.Suresh DPM, Research Medical Officer; K.M.R.Prasad MD, DNB (Psy), Senior Resident; 
Rajesh Mohan DPM, Research Medical Officer; M. VAshok MD, Senior Resident (Formerly); 
S.K.Chaturvedi MD, Additional Professor; K.N.Srcenivas MD, Additional Professor (Reld), 
Department of Psychiatry; Chitiaranjan Andrade MD, Associate Professor, Department of 
Psychopharmacology, National Institute of Mental Health andNeurosciences, Bangalore 560 029. 
* Correspondence: No.8, Type IV, NIMHANS Quarters, Byrasandra, Jayanagar, Bangalore 560 011. 
12 